Evidence map›Paper›PMID 26537674›Full record

ArticleJournal of virology2016

Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.

Florian Douam, Louis-Marie Bobay, Guillemette Maurin, Judith Fresquet, Noémie Calland, Carine Maisse, Tony Durand, François-Loïc Cosset, Cyrille Féray, Dimitri Lavillette

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Florian DouamCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France CNRS, UMR 5557 Microbial Ecology, Microbial Dynamics and Viral Transmission team; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Louis-Marie BobayCNRS, UMR3525, Microbial Evolutionary Genomics, Institut Pasteur, Université Pierre et Marie Curie, Cellule Pasteur UPMC, Paris, France.
Guillemette MaurinCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France.
Judith FresquetCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France.
Noémie CallandCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France.
Carine MaisseINRA, UMR754, ENVL, Rétrovirus et Pathologie Comparée, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Tony DurandUMR913, Institut des Maladies de l'Appareil Digestif (IMAD), Faculté de Médecine, INSERM, Nantes, France.
François-Loïc CossetCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France LabEx Ecofect, Université de Lyon, Lyon, France.
Cyrille FérayINSERM, U955, Groupe Hospitalier Universitaire Albert Chenevier-Henri Mondor, Créteil, France.
Dimitri LavilletteCIRI, International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France INSERM, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France CNRS, UMR5308, Lyon, France CNRS, UMR 5557 Microbial Ecology, Microbial Dynamics and Viral Transmission team; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France dimitri.lavillette@univ-lyon1.fr.
Université Claude Bernard Lyon 1 · FRInserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledHepatitis C virus (HCV) productively infects hepatocytes. Virion surface glycoproteins E1 and E2 play a major role in this restricted cell tropism by mediating virus entry into particular cell types. However, several pieces of evidence have suggested the ability of patient-derived HCV particles to infect peripheral blood mononuclear cells. The viral determinants and mechanisms mediating such events remain poorly understood. Here, we aimed at isolating viral determinants of HCV entry into B lymphocytes. For this purpose, we constructed a library of full E1E2 sequences isolated from serum and B lymphocytes of four chronically infected patients. We observed a strong phylogenetic compartmentalization of E1E2 sequences isolated from B lymphocytes in one patient, indicating that E1E2 glycoproteins can represent important mediators of the strong segregation of two specialized populations in some patients. Most of the E1E2 envelope glycoproteins were functional and allowed transduction of hepatocyte cell lines using HCV-derived pseudoparticles. Strikingly, introduction of envelope glycoproteins isolated from B lymphocytes into the HCV JFH-1 replicating virus switched the entry tropism of this nonlymphotropic virus from hepatotropism to lymphotropism. Significant detection of viral RNA and viral proteins within B cells was restricted to infections with JFH-1 harboring E1E2 from lymphocytes and depended on an endocytic, pH-dependent entry pathway. Here, we achieved for the first time the isolation of HCV viral proteins carrying entry-related lymphotropism determinants. The identification of genetic determinants within E1E2 represents a first step for a better understanding of the complex relationship between HCV infection, viral persistence, and extrahepatic disorders. IMPORTANCE: Hepatitis C virus (HCV) mainly replicates within the liver. However, it has been shown that patient-derived HCV particles can slightly infect lymphocytes in vitro and in vivo, highlighting the existence of lymphotropism determinants within HCV viral proteins. We isolated HCV envelope glycoproteins from patient B lymphocytes that conferred to a nonlymphotropic HCV the ability to enter B cells, thus providing a platform for characterization of HCV entry into lymphocytes. This unusual tropism was accompanied by a loss of entry function into hepatocytes, suggesting that HCV lymphotropic variants likely constitute a distinct but parallel source for viral persistence and immune escape within chronically infected patients. Moreover, the level of genetic divergence of B-cell-derived envelopes correlated with their degree of lymphotropism, underlining a long-term specialization of some viral populations for B-lymphocytes. Consequently, the clearance of both hepatotropic and nonhepatotropic HCV populations may be important for effective treatment of chronically infected patients.

Indexed as

Viral TropismVirus InternalizationB-LymphocytesCell LineHepacivirusHepatitis C, ChronicHepatocytesHumansTransduction, GeneticViral Envelope ProteinsE1 protein, Hepatitis C virusglycoprotein E2, Hepatitis C virusViral Envelope Proteins

Identifiers

PMID26537674
PMCPMC4702674
OpenAlexW2285118397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.